Skip to main content
Top
Published in: Gastric Cancer 6/2023

11-08-2023 | Endoscopy | Case Report

Numerous lesions of gastric adenocarcinoma of fundic-gland and fundic gland-mucosa type in a patient

Authors: Kentaro Imamura, Kenshi Yao, Satoshi Nimura, Hiroshi Tanabe, Takao Kanemitsu, Masaki Miyaoka

Published in: Gastric Cancer | Issue 6/2023

Login to get access

Abstract

A man in his 60 s underwent upper gastrointestinal endoscopy at our hospital, which revealed a 30-mm elevated lesion in the upper stomach (main lesion). There were several discolored, flat mucosal lesions and slightly elevated, reddish, subepithelial mass-like lesions (multiple secondary lesions) in the gastric fornix and body. Histopathological examination of several biopsied secondary lesions revealed gastric adenocarcinoma of fundic-gland type (GA-FG) or gastric adenocarcinoma of fundic gland-mucosa type (GA-FGM). The main lesion was suspected to be GA-FGM on magnifying endoscopy with narrow-band imaging. It was removed using endoscopic submucosal dissection for therapeutic and diagnostic purposes. The histopathological diagnosis of the resected lesion was GA-FGM, which was surrounded by two GA-FGM and > 30 GA-FG lesions. Total gastrectomy was considered; however, the patient declined further surgical treatment. Therefore, he was followed up with biannual endoscopy and computed tomography. At five years postoperatively, no tumor growth or metastasis has been observed.
Literature
1.
go back to reference Ueyama H, Yao T, Nakashima Y, Hirakawa K, Oshiro Y, Hirahashi M, et al. Gastric adenocarcinoma of fundic gland type (chief cell predominant type): proposal for a new entity of gastric adenocarcinoma. Am J Surg Pathol. 2010;34:609–19.CrossRefPubMed Ueyama H, Yao T, Nakashima Y, Hirakawa K, Oshiro Y, Hirahashi M, et al. Gastric adenocarcinoma of fundic gland type (chief cell predominant type): proposal for a new entity of gastric adenocarcinoma. Am J Surg Pathol. 2010;34:609–19.CrossRefPubMed
2.
go back to reference Iwashita A, Tanabe H. Diagnosis of low-grade gastric differentiated adenocarcinoma [in Japanese]. Stomach and Intestine (Tokyo). 2010;45:1057–60. Iwashita A, Tanabe H. Diagnosis of low-grade gastric differentiated adenocarcinoma [in Japanese]. Stomach and Intestine (Tokyo). 2010;45:1057–60.
3.
go back to reference Tanabe H, Iwashita A, Ikeda K, Ota A, Yao K. Histopathological characteristics of gastric adenocarcinoma of fundic gland type [in Japanese]. Stomach and Intestine (Tokyo). 2015;50:1469–79. Tanabe H, Iwashita A, Ikeda K, Ota A, Yao K. Histopathological characteristics of gastric adenocarcinoma of fundic gland type [in Japanese]. Stomach and Intestine (Tokyo). 2015;50:1469–79.
5.
go back to reference Tameez Uddin A, Alam F, Tameez-Uddin A, Chaudhary FM. Auto-brewery syndrome: a clinical dilemma. Cureus. 2020;12:e10983. Tameez Uddin A, Alam F, Tameez-Uddin A, Chaudhary FM. Auto-brewery syndrome: a clinical dilemma. Cureus. 2020;12:e10983.
6.
go back to reference Yao K, Anagnostopoulos GK, Ragunath K. Magnifying endoscopy for diagnosing and delineating early gastric cancer. Endoscopy. 2009;41:462–7.CrossRefPubMed Yao K, Anagnostopoulos GK, Ragunath K. Magnifying endoscopy for diagnosing and delineating early gastric cancer. Endoscopy. 2009;41:462–7.CrossRefPubMed
7.
go back to reference Ueyama H, Matsumoto K, Nagahara A, Hayashi T, Yao T, Watanabe S, et al. Gastric adenocarcinoma of the fundic gland type (chief cell predominant type). Endoscopy. 2014;46:153–7.PubMed Ueyama H, Matsumoto K, Nagahara A, Hayashi T, Yao T, Watanabe S, et al. Gastric adenocarcinoma of the fundic gland type (chief cell predominant type). Endoscopy. 2014;46:153–7.PubMed
8.
go back to reference Imamura K, Yao K, Nimura S, Tanabe H, Kanemitsu T, Miyaoka M, et al. Characteristic endoscopic findings of gastric adenocarcinoma of fundic-gland mucosa type. Gastric Cancer. 2021;24:1307–19.CrossRefPubMed Imamura K, Yao K, Nimura S, Tanabe H, Kanemitsu T, Miyaoka M, et al. Characteristic endoscopic findings of gastric adenocarcinoma of fundic-gland mucosa type. Gastric Cancer. 2021;24:1307–19.CrossRefPubMed
9.
go back to reference Ueyama H, Yao T, Akazawa Y, Hayashi T, Kurahara K, Oshiro Y, et al. Gastric epithelial neoplasm of fundic-gland mucosa lineage: proposal for a new classification in association with gastric adenocarcinoma of fundic-gland type. J Gastroenterol. 2021;56:814–28.CrossRefPubMedPubMedCentral Ueyama H, Yao T, Akazawa Y, Hayashi T, Kurahara K, Oshiro Y, et al. Gastric epithelial neoplasm of fundic-gland mucosa lineage: proposal for a new classification in association with gastric adenocarcinoma of fundic-gland type. J Gastroenterol. 2021;56:814–28.CrossRefPubMedPubMedCentral
10.
go back to reference Okumura Y, Takamatsu M, Ohashi M, Yamamoto Y, Yamamoto N, Kawachi H, et al. Gastric adenocarcinoma of fundic gland type with aggressive transformation and lymph node metastasis: a case report. J Gastric Cancer. 2018;18:409–16.CrossRefPubMedPubMedCentral Okumura Y, Takamatsu M, Ohashi M, Yamamoto Y, Yamamoto N, Kawachi H, et al. Gastric adenocarcinoma of fundic gland type with aggressive transformation and lymph node metastasis: a case report. J Gastric Cancer. 2018;18:409–16.CrossRefPubMedPubMedCentral
11.
Metadata
Title
Numerous lesions of gastric adenocarcinoma of fundic-gland and fundic gland-mucosa type in a patient
Authors
Kentaro Imamura
Kenshi Yao
Satoshi Nimura
Hiroshi Tanabe
Takao Kanemitsu
Masaki Miyaoka
Publication date
11-08-2023
Publisher
Springer Nature Singapore
Published in
Gastric Cancer / Issue 6/2023
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-023-01421-1

Other articles of this Issue 6/2023

Gastric Cancer 6/2023 Go to the issue

Acknowledgment to Reviewers

Acknowledgment to Reviewers

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine